People with eye diseases like neovascular age-related macular degeneration or diabetic macular edema need strong treatments to keep their sight. For years, only one specific version of the drug aflibercept was available. Now, cheaper versions called biosimilars have entered the market. But do they work the same way? A new systematic review and meta-analysis looked at data from 4064 patients to find out.
The researchers compared the biosimilars directly to the original reference aflibercept. They measured how well vision improved and tracked eye thickness and safety. The results were clear: there were no significant differences between the two types of medication. Patients treated with the biosimilar saw vision changes that matched the original drug perfectly.
Safety was also a major concern for doctors and families. The study found no significant differences in treatment-emergent adverse events or ocular adverse effects. There were no reports of serious adverse events or discontinuations. This means the biosimilars are just as safe as the original treatment.
This research offers a cost-effective alternative that offers similar clinical benefits while improving treatment accessibility. If the biosimilars work just as well, patients and insurance plans can save money without risking their vision. The evidence suggests these new options are ready for use.
